Skip to main content

01.12.2015 | Case report | Ausgabe 1/2015 Open Access

Thrombosis Journal 1/2015

Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment

Thrombosis Journal > Ausgabe 1/2015
Norimichi Koitabashi, Nogiku Niwamae, Tetsuya Taguchi, Yoshiaki Ohyama, Noriaki Takama, Masahiko Kurabayashi
Wichtige Hinweise

Competing interests

This case was enrolled in the J-EINSTEIN trial. Publication of this case was approved by the J-EINSTEIN study group. This report was reviewed by Bayer HealthCare.

Authors’ contributions

All authors were involved in the management of the patient. All authors contributed to the draft and revision of the manuscript and approved the final manuscript.


Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is anticoagulant therapy using heparin and a vitamin K antagonist, but a recent clinical study showed that rivaroxaban, an oral Xa inhibitor, was comparable to standard therapy and had less bleeding complications. Intensive high-dose anticoagulation is recommended during the initial 3 weeks of DVT treatment. The present report describes a case of a 77-year-old male showing a remarkable regression of DVT in response to rivaroxaban treatment within the initial 3 weeks of therapy and who did not experience any adverse events. His DVT was massive and was accompanied by proximal iliofemoral vein thrombus and iliac vein compression syndrome. Rivaroxaban, especially in intensive high-dose treatment, might be a safe and effective therapeutic choice for massive DVT.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

Thrombosis Journal 1/2015 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin